Biotech confident of healthier revenue flow

Pacific Edge Biotechnology predicts healthier revenue flows this year as its first products near commercial release after four years of research and development.

The fledgling Dunedin biomedical company reported a net loss for the year to March 31 of $2.85 million, in line with a budgeted loss of that amount.

The company develops diagnostic and therapeutic products to manage cancer and other diseases.